|
Match
|
Document |
Document Title |
|
|
7303749 |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for...
|
|
|
7226601 |
Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the...
|
|
|
7189395 |
Complexes of immunoglobulins and polysaccharides for oral and transmucosal absorption
The present invention relates to complexes consisting of immunoglobulins and polysaccharides for oral and transmucosal use. The polysaccharides comprised in the complexes according to the...
|
|
|
7147849 |
Pharmaceutical formulation
A pharmaceutical formulation containing at least one protein-containing substance and at least one substance selected from the group of compatible solutes.
|
|
|
7135185 |
Conserved motif of hepatitis C virus E2/NS1 region
Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence...
|
|
|
7060495 |
Fusion proteins for prodrug activation
The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity...
|
|
|
6998125 |
Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis....
|
|
|
6977075 |
Photosensitizer conjugates for targeting intracellular pathogens
The methods of the invention can be used to treat mycobacterial infections, or any disease or disorder that is caused by (or aggravated by) an intracellular pathogen. Accordingly, the invention...
|
|
|
6962694 |
Cytolysis of target cells by superantigen conjugates inducing T-cell activation
A method for inactivating target cells in the presence of T cells by bringing the two types of cells in contact with a superantigen (SAG) in the presence of an immune modulator, characterized in...
|
|
|
6808930 |
Therapeutic agents
An agent comprising a protein complex comprising an oligomeric form of α-lactalbumin (MAL) and a further reagent which is combined with MAL such that it is carried into the nucleoplasm of cells...
|
|
|
6749853 |
Combined methods and compositions for coagulation and tumor treatment
Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor...
|
|
|
6610298 |
Photosensitzer conjugates for targeting intracellular pathogens
The methods of the invention can be used to treat mycobacterial infections, or any disease or disorder that is caused by (or aggravated by) an intracellular pathogen. Accordingly, the invention...
|
|
|
6562801 |
PpGpp and pppGpp as immunomodulatory agents
The present invention relates generally to the fields of immunopreventive therapy and vaccine development. More particularly, it concerns compositions and methods of use of the bacterial...
|
|
|
6548644 |
Site protected protein modification
Processes for conjugating proteins with polyethylene glycol are disclosed. The disclosed processes provide modified proteins having little or no decrease in their activity and include the steps of...
|
|
|
6548067 |
Antigenic constructs of major histocompatibility complex class I antigens with specific carrier molecules, the preparation and use thereof
Antigenic constructs which result from linkage of major histocompatibility complex (MHC) class I antigens with specific carrier molecules are described. The linkage is effected N- or C-terminally...
|
|
|
6406679 |
Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells
Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment...
|
|
|
6368598 |
Drug complex for treatment of metastatic prostate cancer
A drug complex for delivery of a drug or other agent to a target cell, comprising a targeting carrier molecule which is selectively distributed to a specific cell type or tissue containing the...
|
|
|
6348195 |
Method for treating cancers
The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all...
|
|
|
6143297 |
Methods of promoting immunopotentiation and preparing antibodies with anti-CD3 antibodies
Disclosed are immunopotentiating agents, and vaccines thereof, which enhance and/or otherwise modify immune responses, and method for their preparation and use in vivo. Immunopotentiating agents...
|
|
|
6113900 |
Use of IL-2 receptor-targeted therapeutics to inhibit allograft rejection and treat autoimmune disorders
Methods of inhibiting allograft rejection and of inhibiting B lymphocyte-mediated autoimmune diseases are provided. The methods involve the use of agents specific for the IL-2 receptor, such as...
|
|
|
6093399 |
Methods and compositions for the specific coagulation of vasculature
Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor...
|
|
|
6093391 |
Peptide copolymer compositions
Compositions of peptides and block copolymers and methods of treatment using the same. The compositions enhance the activity of peptide-based and related biological agents, and reduce adverse side...
|
|
|
6074643 |
Site-directed chemotherapy of metastases
Provided for use in site-directed chemotherapy are compositions comprising chemotherapeutic agents targeted to either arrested metastatic cells via a cell-surface marker associated with metastasis;...
|
|
|
6051230 |
Compositions for targeting the vasculature of solid tumors
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects,...
|
|
|
6022541 |
Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel
The present invention provides an immunological preparation comprising not less than two types of conjugate molecules in admixture for concurrent specific binding to a spatially exposed region of...
|
|
|
6004554 |
Methods for targeting the vasculature of solid tumors
The present invention relates generally to methods and compositions for targeting the vasulature of solid tumors using immunologcially-based reagents. In particular aspects, antibodies carrying...
|
|
|
5985281 |
Chemical compounds
A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme...
|
|
|
5976535 |
Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
Methods for targeting cytotoxins to target sites by administration of a combination of conjugates are provided. Novel cytotoxic combinations for use in such methods are also provided.
|
|
|
5928643 |
Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation
Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those...
|
|
|
5916559 |
Use of interleukin-2 (IL-2) receptor-specific agents to treat allograft rejection
A method of lysing unwanted, non-malignant cells in a mammal, the cells having on their surfaces a receptor for a growth factor, and the method including administering to the mammal a cell-lysing...
|
|
|
5914111 |
CD2-binding domain of lymphocyte function associated antigen-3
Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those...
|
|
|
5783181 |
Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins
A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity comprises an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
|
|
|
5705158 |
Treatment of infectious and inflammatory lesions
A polyspecific anti-leukocyte antibody conjugate for targeting foci of leukocyte accretion comprises an immunoreactive polyspecific composite of at least two different substantially monospecific...
|
|
|
5674494 |
Treating non-malignant disease states with IL-2 receptor-specific substances
Methods of treating a non-malignant, disease state-producing immune response in a mammal are provided. The methods involve administering to the mammal an IL-2 receptor-specific substance during a...
|
|
|
5665357 |
Antibodies recognizing tumor associated antigen CA 55.1
Antibodies which recognize a tumor related antigen designated CA55.1 such as hybridoma 55.1 deposited as ECACC deposit no. 93081901 in which the complementarity determining regions have the...
|
|
|
5662905 |
Monoclonal antibody compositions cross-reactive and cross-protective against P. aeruginosa serotypes
Cell lines have been produced that secrete human monoclonal antibodies capable of binding to the lipopolysaccharide molecules of selected Pseudomonas aeruginosa IATS serotypes. Pharmaceutical...
|
|
|
5660829 |
Process for antibody directed enzyme prodrug therapy
Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic...
|
|
|
5648059 |
Methods for reducing non-target retention of immunoconjugates and metabolites thereof
Methods for reducing non-target retention of active moieties associated with immunoconjugates and their metabolites, and more specifically, for reducing renal retention of such active moieties, are...
|
|
|
5607675 |
Treatment of autoimmune diseases with IL-2 receptor-specific cytotoxin
A method of treating a mammal suffering from an autoimmune disease state is provided. The method comprises administering to the mammal a cytotoxin-conjugated IL-2 receptor-specific substance during...
|
|
|
5587162 |
Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
Methods of inhibiting the rejection and prolonging the survival of an allograft in a mammal are provided. The methods involve administering to the mammal a cytotoxin-conjugated IL-2...
|
|
|
5496549 |
Bispecific monoclonal antibodies, thrombolytic agent and method of cell lysis
Disclosed are a bispecific hybrid MoAb having specificity for both an activated platelet and a substance having thrombolytic activity, and a thrombolytic agent comprising the above bispecific MoAb...
|
|
|
5399338 |
Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
Biomodulators, in conjunction with antibodies, tumor-specific agents or conjugates thereof, optionally linked to imaging-active moieties, can be administered to a host to enhance images thereof,...
|
|
|
5395924 |
Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
An activated affinity ligand is described comprising: a ligand having (a) a region with affinity for binding sites of a lectin; and (b) a reactive group capable of covalently linking the ligand to...
|
|
|
5362491 |
Modified biologically active protein composition
A composition which comprises a modified biologically active protein consisting essentially of a biologically active protein bonded to lecithin via a covalent linkage and a protein inhibitor which...
|
|
|
5144009 |
Conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, their use as immunotoxin potentiators and the intermediate activated inophores
The present invention relates to conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule chosen from antibodies, fragments of...
|
|
|
5112607 |
Potentiation of immunotoxin action by Brefeldin A
A method of potentiating immunotoxin action in an immunotoxin/target-cell stem in which Brefeldin A is utilized as an immunopotentiator. The Brefeldin A enhances the immunotoxin pathway while...
|
|
|
5055289 |
Interferon antibody therapeutic compositions having an extended serum half-life
A complex of alpha-interferon with a monoclonal antibody complexes with the alpha-interferon without impairing its antiviral activity. The serum half-life of the interferon administered as the...
|
|
|
4962188 |
Recombinant ricin toxin A chain conjugates
Conjugates comprising recombinant ricin toxin A chain and a binding moiety which may be an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab') 2 fragments of...
|
|
|
4946675 |
Hepatic blocking agents
Novel methods and compositions are provided for the enhancement of the biodistribution of immunoconjugates useful in the diagnosis and treatment of a variety of conditions including cancer in many...
|
|
|
4925922 |
Potentiation of cytotoxic conjugates
Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on...
|